SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Lillys ESMO oncology updates, especially early ovarian-cancer data for Sofe-M with bevacizumab, are drawing attention as investors weigh the pipelines potential to diversify beyond obesity drugs. Traders are also discussing olomorasib lung-cancer findings, while the stocks pullback has prompted mixed reactions about whether the positive pipeline news can support further gains.

Caterpillar, Inc. engages in the business of manufacturing construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. It operates through the following segments: Construction Industries, Resource Industries, Power and Energy, and All Other. The Construction Industries segment is involved in supporting customers using machinery in infrastructure and building construction applications. The Resource Industries segment offers machinery in mining, heavy construction, quarry, and aggregates. The Power and Energy segment focuses on reciprocating engines, turbines, diesel-electric locomotives, and related services across industries serving oil and gas, power generation, industrial, and transportation applications including marine- and rail-related businesses. The All Other segment includes activities such as the business strategy, product management and development, manufacturing, and sourcing of wear and maintenance components products, parts distribution, integrated logistics solutions, distribution services responsible for dealer development, and administration. The company was founded on April 15, 1925, and is headquartered in Irving, TX.

Caterpillar Inc.

Caterpillars upcoming quarterly report is the main focus as shares pull back sharply, with traders debating whether strong backlog and data-center power demand can withstand already-high expectations. Some expect further downside if guidance or orders disappoint, while others view the oversold pullback as a buying opportunity.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

Phase 2 results for pumitamig plus docetaxel in advanced lung cancer are drawing attention, with traders weighing the reported response rate and progression-free survival against questions about how durable the benefit will be. The reaction is tempered by broader concerns about BioNTechs earlier clinical setbacks and leadership transition.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ousters volatile share-price swings and pullback are driving debate, with bullish traders buying dips ahead of earnings and pointing to Rev8 lidar deployments and customer partnerships in agriculture, mapping, and autonomous systems. Others question the valuation and pace of commercial adoption, leaving the Physical AI growth case weighed against execution risk.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Positive prostate-cancer trial results are drawing attention, including reports of lower recurrence risk with ERLEADA and a tumor-response signal for an early-stage treatment. Traders see the data as supportive but debate whether it can move the shares meaningfully or is already priced in.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

AXSMs steep selloff has centered on uncertainty over Auvelitys launch for Alzheimers agitation, as prescription data has not shown the acceleration some investors expected; the Nov. 2 Q3 report is widely viewed as a key test of uptake and commercial execution. Some traders fear weak adoption and rising expenses, while others argue that samples and long-term-care prescriptions may be undercounted and remain bullish on the launchs longer-term potential.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

GLXY is drawing attention ahead of its earnings report as traders debate whether results can halt a sharp selloff tied to weakness in crypto and AI/data-center stocks. Bearish posts fear disappointing results and exposure to CoreWeave, while some investors see the decline as overdone and are positioning for a rebound.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Crypto-market volatility and Coinbases upcoming quarterly report are driving attention, with traders focused on the stocks sharp swings and repeated underperformance versus Bitcoineven during crypto rebounds. Sentiment is largely frustrated and bearish over the weak price action and declining revenue trend, though some expect earnings or a crypto recovery to support a bounce.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Ciscos pullback and range-bound trading are drawing attention despite strong AI-networking demand and solid results; traders often point to Piper Sandlers lower price target and concerns that industry growth or valuation may be peaking. Bulls view the weakness as a buying opportunity tied to AI infrastructure spending, while bears remain focused on poor momentum and growth concerns.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

KTOS is drawing attention after a prolonged selloff toward 52-week lows, with traders debating analyst downgrades, insider selling, valuation and whether the company can turn its defense-contract pipeline into stronger profits and cash flow. Some see the pullback as overdone given reported contract wins and drone, hypersonics and space demand, while others are cautious ahead of the Q3 report.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ABVX Stock Clocks Best Day In 11 Months On Analyst Upgrades After Fresh Data Eases Drug Safety Concerns 

Equity

Wedbush, BTIG and Jefferies weighed in on ABVX on Tuesday after the company unveiled updated safety and efficacy data from an obefazimod study. 


ABVX Stock Rockets 28% After Abivax Eases Drug Safety Concerns With Fresh Clinical Data

Abivax said the findings strengthen the overall case for obefazimod and reinforce its favorable benefit-risk profile.


ABVX Stock Clocks Worst Day Ever On Malignancy Signal For Drug: ‘Pharma Bro’ Says ‘GLPs Are Doing Fine’ After Similar Fears  

Shares of ABVX closed down 44% on Tuesday, clocking its worst day ever, on reports of a number of non-melanoma skin cancers and other malignancies observed in its ulcerative colitis trial. 


ABVX Tanks 30% After-Hours Despite 51% Remission In Ulcerative Colitis Trial — Rare Cancer Concerns Hit Sentiment

The company dismissed the cancers observed in the trial as rare, occurring primarily in older patients, and largely unrelated to treatment. 


Goldman Sachs ETF Trust - Goldman Sachs Hedge IND VIP ETF

Neutral Sentiment

<ul class="summary-bullets"><li>BTIG raised its price target on Abivax to $175 from $150 and maintained a Buy rating.</li><li>Wedbush said that it remains concerned about how the FDA will view cancer risk and the potential for a Black Box warning.</li><li>Abivax also announced on Tuesday the launch of an underwritten public offering of around $600 million in American Depositary Shares.</li></ul><p>Shares of Abivax (ABVX) clocked their best day in about 11 months on Tuesday on the heels of multiple price target revisions and updated safety and efficacy data from a study that addressed prior investor worries about cancer risk tied to its ulcerative colitis candidate, obefazimod.</p><p>ABVX stock closed 39% higher and slipped marginally by 0.15% after-hours, at the time of writing, after the company announced a $600-million public offering.</p><h2 class="st-heading-2">Trial Data</h2><p>Abivax <a href="https://stocktwits.com/news-articles/markets/equity/abvx-stock-rockets-after-abivax-eases-drug-safety-concerns-with-fresh-clinical-data/cZ19pPuR7L8">released</a> the updated study data after-hours on Monday. The data showed malignancy rates, including non-melanoma skin cancers, remained consistent with background rates in ulcerative colitis patients. Four NMSC cases were reported in Part 2 of the trial—two per dose arm—mostly in patients with pre-existing risk factors, while two additional non-NMSC malignancies in the 50 mg group were deemed unrelated to the drug.</p><p>Abivax said the data reinforce obefazimod’s favorable benefit-risk profile. More than one-third of patients in the higher-dose group achieved clinical remission and mucosal healing at week 44. The company plans to submit a U.S. FDA new drug application in the fourth quarter.</p><h2 class="st-heading-2">Wall Street Weighs In</h2><p>BTIG raised its price target on Abivax to $175 from $150 and maintained a Buy rating. The analyst said the latest update provided additional safety data confirming a sufficiently clean safety profile for obefazimod. BTIG’s new price target represents a potential upside of about 31% from the stock’s closing price on Tuesday.</p><p>Wedbush analyst David Nierengarten raised the firm’s price target to $110 from $90 but kept a Neutral rating. While the pooled safety data appeared in line with background malignancy rates in ulcerative colitis, Wedbush remains concerned about how the FDA will view cancer risk and the potential for a Black Box warning. Nierengarten’s new price target assumed a potential downside of about 17% from the stock’s closing price.</p><p>Jefferies upgraded Abivax to Buy from Hold and lifted its price target to $158 from $108, representing a potential upside of nearly 19% from the stock’s last close. The firm said the Part 2 update “appropriately addresses the key overhang facing the stock” and that management did a good job addressing investor concerns with the presentation of the safety data. Jefferies also noted that the efficacy profile continues to strengthen with additional data.</p><h2 class="st-heading-2">Abivax Launches $600-Million Public Offering</h2><p>Separately, Abivax announced on Tuesday the launch of an underwritten public offering of around $600 million in American Depositary Shares. The company intends to use the net proceeds for U.S. commercialization expenses of obefazimod, clinical development in ulcerative colitis and Crohn’s disease, and general corporate purposes.</p><h2 class="st-heading-2">How Did ABVX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around ABVX stayed within the ‘bullish’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘high’ levels.</p><p>A Stocktwits user opined that the capital raise is to convince interested partners that the company can also move forward solo.</p><p><stembedurl>https://www.stocktwits.com/Miles223/message/657970692</stembedurl></p><p>Another user echoed the sentiment, positioning the capital raise as proof that the company received “lowball M&amp;A offers.”</p><p><stembedurl>https://www.stocktwits.com/p3akyblinder/message/657971234</stembedurl></p><p>A third user voiced hopes for an imminent near-term buyout for the company.</p><p><stembedurl>https://www.stocktwits.com/MZ2X/message/657969299</stembedurl></p><p><a href="https://stocktwits.com/symbol/ABVX">ABVX stock</a> has traded nearly flat year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/uncy-stock-clocks-worst-day-in-year-analysts-keep-buy-ratings-despite-5-12-month-delay-in-drug-approval/cZ1QMSoR70o">UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Abivax logo is seen displayed on a smartphone screen

Wedbush, BTIG and Jefferies weighed in on ABVX on Tuesday after the company unveiled updated safety and efficacy data from an obefazimod study. 

Abivax - ADR

iShares Biotechnology ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$159.53
Prev Close	$160.37
Open	$159.55
Dividend Yield	N/A
50-Day Moving Average	$170.56
Beta	N/A
Avg. Volume	8,927.19
PE Ratio	N/A

52-Week High	$192.13
52-Week Low	$138.73
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

GVIP Fundamentals